A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 6, 2009, Pages 1181-1185

  Totani, Yoshitaka ^a   Saito, Yuji ^a   Hayashi, Masamichi ^a   Tada, Toshihiko ^a   Kohashi, Yasuo ^a   Mieno, Yuki ^a   Kato, Atsushi ^a   Imizu, Hiromi ^a   Yoneda, Yukiko ^a   Hoshino, Tami ^a   Uchiyama, Yasuhiro ^a   Takeuchi, Yasuo ^a   Okazawa, Mitsushi ^a   Sakakibara, Hiroki ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Non small cell lung cancer (NSCLC); Oral cytotoxic agent; S 1; Second line chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATIONS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; OXONIC ACID; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 69049087656     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0981-1     Document Type: Article

References (16)

1. RT Greenlee T Murray S Bolden PA Wingo 2000 Cancer statistics, 2000 CA Cancer J Clin 50 7 33
2. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook J Zhu DH Johnson Eastern Cooperative Oncology Group 2002 Comparison of four chemotherapy regimens for advanced non-small cell lung cancer N Engl J Med 346 2 92 98
3. EF Smit JP van Meerbeeck P Lianes C Debruyne C Legrand F Schramel H Smit R Gaafar B Biesma C Manegold N Neymark G Giaccone European Organization for Research, Treatment of Cancer Lung Cancer Group 2003 Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group, EORTC 08975 J Clin Oncol 21 21 3909 3917
4. FA Shepherd J Dancey R Ramlau K Mattson R Gralla M O'Rourke N Levitan L Gressot M Vincent R Burkes S Coughlin Y Kim J Berille 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 10 2095 2103
5. FV Fossella R DeVore RN Kerr J Crawford RR Natale F Dunphy L Kalman V Miller JS Lee M Moore D Gandara D Karp E Vokes M Kris Y Kim F Gamza L Hammershaimb 2000 Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 18 12 2354 2362
6. N Hanna FA Shepherd FV Fossella JR Pereira F De Marinis J von Pawel U Gatzemeier TC Tsao M Pless T Muller HL Lim C Desch K Szondy R Gervais C Manegold Shaharyar S Paul P Paoletti L Einhorn PA Bunn Jr 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy J Clin Oncol 22 9 1589 1597
7. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabárbara L Seymour National Cancer Institute of Canada Clinical Trials Group 2005 Erlotinib in previously treated non-small cell lung cancer N Engl J Med 353 2 123 132
8. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura M Fukushima 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 5 548 557
9. T Shirasaka Y Shimamoto M Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 17 4004 4009
10. M Kawahara K Furuse Y Segawa K Yoshimori K Matsui S Kudoh K Hasegawa H Niitani 2001 Phase II study of S-1, a novel oral fluorouracil, in advanced non-small cell lung cancer Br J Cancer 85 7 939 943
11. D Rossi V Catalano P Alessandroni A Fedeli SL Fedeli P Giordani AM Baldelli V Casadei M Ceccolini M Ugolini D Dennetta G Catalano 2007 A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small cell lung cancer Clin Lung Cancer 8 6 382 385
12. K Furuse M Kawahara K Hasegawa S Kudoh M Takada T Sugiura Y Ichinose M Fukuoka Y Ohashi H Niitani 2001 Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small cell lung cancer Int J Clin Oncol 6 5 236 241
13. 2) docetaxel in patients with advanced non-small cell lung cancer Cancer Chemother Pharmacol 48 5 356 360
14. Y Ichinose K Yoshimori H Sakai Y Nakai T Sugiura M Kawahara H Niitani 2004 S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial Clin Cancer Res 10 23 7860 7864
15. R Ramlau R Gervais M Krzakowski J von Pawel E Kaukel RP Abratt B Dharan KM Grotzinger G Ross G Dane FA Shepherd 2006 Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small cell lung cancer J Clin Oncol 24 18 2800 2807 Epub 2006 May 8
16. P Baas A Szczesna I Albert J Milanowski E Juhász Z Sztancsik J von Pawel R Oyama S Burgers 2008 Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer J Thorac Oncol 3 7 745 750